Employers have a unique opportunity to shift from reactive to proactive care, in an unprecedented way. By grounding benefits strategies in clinical innovation and time-tested behavior change, healthy aging and enhanced quality of life is more achievable than ever before.
As scientists and researchers figure out the right balance of GLP-1 to glucagon ratio and a better drug delivery method, we are beginning to turn the page for the many individuals suffering from obesity.
Explore top-tier aesthetic certification programs that blend theory with hands-on training — perfect for health care pros ready to elevate their practice
The Phase 3 results in China are encouraging for Kailera Therapeutics, which holds rights to the molecule in the rest of the world. The startup is preparing a global clinical development program for this drug, a once-weekly injectable GLP-1 and GIP receptor agonist.
This lawsuit may look like a business dispute on the surface. But underneath, it’s about something much more important: the right of patients to receive personalized, affordable care.
GLP-1s are a breakthrough, but they are not the end of the story. To ensure lasting success, we must pair pharmacological interventions with behavioral support, personalized data, and continuous guidance.
Novo Nordisk, AbbVie, and Roche each have weekly injectable drug candidates designed to bind to and activate the amylin receptor to trigger weight loss. Metsera’s contender, MET-233i, is designed with technology that enables longer dosing intervals and the company is proceeding with development of this engineered peptide as a monotherapy and as part of a drug combination.
Break down the silos. Take control of your provider data.
Healthcare and benefits leaders must step up to provide menopausal women with the full-spectrum care they need to protect musculoskeletal and metabolic health for lifelong strength and well-being.
As healthcare costs continue to rise, three data-driven strategies can help companies reduce the expense of employee health benefits – without sacrificing quality.
GLP-1 medications are transforming how we think about chronic disease management and, more importantly, prevention. Ongoing research has found them to be effective in the prevention or treatment of diabetes, heart attacks and strokes, kidney disease, liver disease, sleep apnea, and more.
Pfizer said a patient dosed with danuglipron developed potential drug-induced liver injury. Pfizer is stopping further work on this program, a move that comes nearly two years after it discontinued development of a different obesity drug due to liver safety signals in a clinical trial.
A new report by Paubox calls for healthcare IT leaders to dispose of outdated assumptions about email security and address the challenges of evolving cybersecurity threats.
Engaging in data sharing, observational cohort research, and deeper analysis of available data to yield further insights can drive improved results for patients, making label and cohort extension faster and more robust.
CagriSema, a dual-acting drug in development by Novo Nordisk, met the goal of a Phase 3 test in patients with obesity and type 2 diabetes. But the topline results don’t show an advantage over Eli Lilly’s commercialized obesity medication, Zepbound.
For GLP-1 receptor agonists specifically, adherence challenges are a major concern, as these medications require long-term use to achieve meaningful health benefits in chronic conditions like diabetes and obesity.
Compounded GLP-1s have become more widespread, but are they safe? Some argue that compounding is nothing new, while others believe these drugs are dangerous for patients.
Regulators will have their work cut out for them under a new administration that has expressed an anti-regulatory preference. Republicans next year will control the White House, Senate and House. What will it all mean for pharmacy leaders?